论文部分内容阅读
目的探讨趋化因子5(CXCL5)在喉鳞状细胞癌(鳞癌)中的表达水平及其与临床分期、分化程度、淋巴转移及预后等临床病理参数的关系。方法用免疫组化法检测CXCL5蛋白在95例喉鳞癌组织和36例声带息肉(对照组)组织中的表达,分析其与临床病理学特征的关系。KaPlan-Meier法与Log-rank检验分析生存情况。结果CXCL5蛋白在喉鳞癌组和对照组的阳性高表达率分别为61.1%和19.4%(P<0.05),其表达分别在不同的临床分期、T分期及淋巴转移之间差异有统计学意义(P值均<0.05),而在性别、年龄、吸烟、分化程度及分型之间差异无统计学意义(P值均>0.05);单因素分析结果显示喉癌患者CXCL5蛋白高表达组比CXCL5低表达组的生存时间更短,临床分期、T分期、淋巴结是否转移、分化程度对生存时间的影响有统计学意义(P值均<0.05),而年龄、性别、吸烟与患者的预后无关(P值均>0.05)。结论 CXCL5蛋白高表达可能是影响喉鳞癌预后的重要因素。CXCL5蛋白可能是肿瘤生物轴重要的靶点,为喉癌早期浸润的诊断和治疗提供新的实验依据。
Objective To investigate the expression of chemokine 5 (CXCL5) in laryngeal squamous cell carcinoma (SCC) and its relationship with clinical stage, differentiation, lymph node metastasis and prognosis. Methods The expressions of CXCL5 protein in 95 cases of laryngeal squamous cell carcinoma and 36 cases of vocal cord polyp (control group) were detected by immunohistochemistry. The relationship between CXCL5 protein and clinicopathological features was analyzed. KaPlan-Meier method and Log-rank test to analyze the survival. Results The positive rates of CXCL5 protein expression in the LSCC group and the control group were 61.1% and 19.4%, respectively (P <0.05). The expressions of CXCL5 protein were significantly different between different clinical stage, T stage and lymphatic metastasis (P <0.05), but there was no significant difference in sex, age, smoking, differentiation and type (P> 0.05). The results of univariate analysis showed that the expression of CXCL5 protein in laryngeal cancer patients CXCL5 low expression group survival time is shorter, clinical stage, T stage, lymph node metastasis, the degree of differentiation of the survival time was statistically significant (P <0.05), while age, gender, smoking and the prognosis of patients has nothing to do (P> 0.05). Conclusion The high expression of CXCL5 may be an important factor affecting the prognosis of LSCC. CXCL5 protein may be an important tumor biological axis target for the diagnosis and treatment of early laryngeal cancer invasion and provide a new experimental basis.